Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2025)

NewAmsterdam Pharma's Research & Development history spans 3 years, with the latest figure at $38.6 million for Q4 2025.

  • For Q4 2025, Research & Development rose 10.6% year-over-year to $38.6 million; the TTM value through Dec 2025 reached $141.8 million, down 6.32%, while the annual FY2025 figure was $141.8 million, 6.32% down from the prior year.
  • Research & Development for Q4 2025 was $38.6 million at NewAmsterdam Pharma, up from $31.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $44.8 million in Q1 2025 and bottomed at $27.5 million in Q2 2025.
  • The 3-year median for Research & Development is $38.5 million (2024), against an average of $37.7 million.
  • The largest annual shift saw Research & Development grew 11.76% in 2024 before it fell 28.3% in 2025.
  • A 3-year view of Research & Development shows it stood at $41.3 million in 2023, then decreased by 15.49% to $34.9 million in 2024, then rose by 10.6% to $38.6 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Research & Development are $38.6 million (Q4 2025), $31.0 million (Q3 2025), and $27.5 million (Q2 2025).